Fundraising FoxAPIM Therapeutics
1 known investors
Find your way into APIM Therapeutics
APIM Therapeutics is a clinical-stage oncology company developing first-in-class PCNA-targeting peptide therapeutics that disrupt cellular stress responses and address treatment resistance in cancer. Its lead candidate, ATX-101, has been evaluated in Phase Ib and Phase II clinical studies for ovarian cancer and soft tissue sarcoma.
Investors · 1
Frequently asked questions
- What does APIM Therapeutics do?
- APIM Therapeutics is a clinical-stage oncology company developing first-in-class PCNA-targeting peptide therapeutics that disrupt cellular stress responses and address treatment resistance in cancer. Its lead candidate, ATX-101, has been evaluated in Phase Ib and Phase II clinical studies for ovarian cancer and soft tissue sarcoma.
- Who are APIM Therapeutics's investors?
- APIM Therapeutics's investors include Birk Venture.